AI ‘Simulants’ Could Save Time and Money on New Medications

Written By Andrea Vuturo

Artificial intelligence is poised to make clinical trials and drug development faster, cheaper, and more efficient. Part of this strategy is creating "synthetic control arms" that use data to create “simulants,” or computer-generated “patients” in a trial. 

Andrea Vuturo
Previous

Alliance for Artificial Intelligence Publishes New Whitepaper: “The Future of Healthcare Is Human”
Next

Can AI Drive More Diversity in Drug Development?